SEARCH

SEARCH BY CITATION

References

  • 1
    Jones PA,Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 41528.
  • 2
    Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 22331.
  • 3
    Bamberger AM,Bamberger CM,Schulte HM. Molecular mechanisms of proliferation in endometrial tumour cells. Hum Reprod Update 1998; 4: 52631.
  • 4
    Nemos C,Delage-Mourroux R,Jouvenot M,Adami P. Onset of direct 17-beta estradiol effects on proliferation and c-fos expression during oncogenesis of endometrial glandular epithelial cells. Exp Cell Res 2004; 296: 10922.
  • 5
    Shiozawa T,Miyamoto T,Kashima H,Nakayama K,Nikaido T,Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 2004; 23: 860310.
  • 6
    Shen Q,Uray IP,Li Y,Krisko TI,Strecker TE,Kim HT,Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008; 27: 36677.
  • 7
    Maggiolini M,Vivacqua A,Fasanella G,Recchia AG,Sisci D,Pezzi V,Montanaro D,Musti AM,Picard D,Andò S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 2700816.
  • 8
    Gründker C,Günthert AR,Hellriegel M,Emons G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004; 151: 61928.
  • 9
    Duan R,Xie W,Burghardt RC,Safe S. Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J Biol Chem 2001; 276: 115908.
  • 10
    Duan R,Xie W,Li X,McDougal A,Safe S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002; 294: 38494.
  • 11
    Hill CS,Marais R,John S,Wynne J,Dalton S,Treisman R. Functional analysis of a growth factor-responsive transcription factor complex. Cell 1993; 73: 395406.
  • 12
    Poser S,Impey S,Trinh K,Xia Z,Storm DR. SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. EMBO J 2000; 19: 495566.
  • 13
    Chen F,Kook H,Milewski R,Gitler AD,Lu MM,Li J,Nazarian R,Schnepp R,Jen K,Biben C,Runke G,Mackay JP, et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 2002; 110: 71323.
  • 14
    Shin CH,Liu ZP,Passier R,Zhang CL,Wang DZ,Harris TM,Yamagishi H,Richardson JA,Childs G,Olson EN. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 2002; 110: 72535.
  • 15
    Kook H,Lepore JJ,Gitler AD,Lu MM,Wing-Man Yung W,Mackay J,Zhou R,Ferrari V,Gruber P,Epstein JA. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003; 112: 86371.
  • 16
    Asanoma K,Matsuda T,Kondo H,Kato K,Kishino T,Niikawa N,Wake N,Kato H. NECC1, a candidate choriocarcinoma suppressor gene that encodes a homeodomain consensus motif. Genomics 2003; 81: 1525.
  • 17
    Chen Y,Petersen S,Pacyna-Gengelbach M,Pietas A,Petersen I. Identification of a novel homeobox-containing gene, LAGY, which is downregulated in lung cancer. Oncology 2003; 64: 4508.
  • 18
    Lemaire F,Millon R,Muller D,Rabouel Y,Bracco L,Abecassis J,Wasylyk B. Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma. Br J Cancer 2004; 91: 25861.
  • 19
    Toruner GA,Ulger C,Alkan M,Galante AT,Rinaggio J,Wilk R,Tian B,Soteropoulos P,Hameed MR,Schwalb MN,Dermody JJ. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004; 154: 2735.
  • 20
    Yamashita K,Kim MS,Park HL,Tokumaru Y,Osada M,Inoue H,Mori M,Sidransky D. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. Mol Cancer Res 2008; 6: 3141.
  • 21
    Kyo S,Nakamura M,Kiyono T,Maida Y,Kanaya T,Tanaka M,Yatabe N,Inoue M. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003; 163: 225969.
  • 22
    Asanoma K,Kato H,Yamaguchi S,Shin CH,Liu ZP,Kato K,Inoue T,Miyanari Y,Yoshikawa K,Sonoda K,Fukushima K,Wake N. HOP/NECC1, a novel regulator of mouse trophoblast differentiation. J Biol Chem 2007; 282: 2406574.
  • 23
    Wilkinson DG,Nieto MA. Detection of messenger RNA by in situ hybridization to tissue sections and whole mounts. Methods Enzymol 1993; 225: 36173.
  • 24
    Yin Z,Gonzales L,Kolla V,Rath N,Zhang Y,Lu MM,Kimura S,Ballard PL,Beers MF,Epstein JA,Morrisey EE. Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulmonary gene expression. Am J Physiol Lung Cell Mol Physiol 2006; 291: L1919.
  • 25
    Vivacqua A,Bonofiglio D,Recchia AG,Musti AM,Picard D,Andò S,Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 63146.
  • 26
    Horner-Glister E,Maleki-Dizaji M,Guerin CJ,Johnson SM,Styles J,White IN. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signaling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 2005; 35: 42132.
  • 27
    Kanaya T,Kyo S,Maida Y,Yatabe N,Tanaka M,Nakamura M,Inoue M. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003; 22: 235260.
  • 28
    Arafa M,Kridelka F,Mathias V,Vanbellinghen JF,Renard I,Foidart JM,Boniver J,Delvenne P. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 2008; 53: 52532.
  • 29
    Mutter GL,Ince TA,Baak JP,Kust GA,Zhou XP,Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001; 61: 43114.
  • 30
    Talbi S,Hamilton AE,Vo KC,Tulac S,Overgaard MT,Dosiou C,Le Shay N,Nezhat CN,Kempson R,Lessey BA,Nayak NR,Giudice LC. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 2006; 147: 1097121.
  • 31
    Chen Y,Pacyna-Gengelbach M,Deutschmann N,Niesporek S,Petersen I. Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int J Cancer 2007; 121: 10217.
  • 32
    Urich M,Senften M,Shaw PE,Ballmer-Hofer K. A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. Oncogene 1997; 14: 123541.
  • 33
    Ding W,Witte MM,Scott RE. Transformation blocks differentiation-induced inhibition of serum response factor interactions with serum response elements. Cancer Res 1999; 59: 3795802.
  • 34
    Iwahara T,Akagi T,Shishido T,Hanafusa H. CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene 2003; 22: 594657.
  • 35
    Keller PJ,Gable CM,Wing MR,Cox AD. Rac3-mediated transformation requires multiple effector pathways. Cancer Res 2005; 65: 988390.
  • 36
    Lin H,McGrath J,Wang P,Lee T. Cellular toxicity induced by SRF-mediated transcriptional squelching. Toxicol Sci 2007; 96: 8391.
  • 37
    Lowe WL,Jr,Fu R,Banko M. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3′,5′-monophosphate in MCF-7 breast cancer cells. Endocrinology 1997; 138: 221926.
  • 38
    Kim B,Leventhal PS,Saltiel AR,Feldman EL. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation. J Biol Chem 1997; 272: 2126873.
  • 39
    Wu W,Pew T,Zou M,Pang D,Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280: 411724.
  • 40
    Moelling K,Schad K,Bosse M,Zimmermann S,Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277: 31099106.
  • 41
    Marino M,Acconcia F,Trentalance A. Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 2003; 14: 258391.
  • 42
    Gervais M,Dugourd C,Muller L,Ardidie C,Canton B,Loviconi L,Corvol P,Chneiweiss H,Monnot C. Akt down-regulates ERK1/2 nuclear localization and angiotensin II-induced cell proliferation through PEA-15. Mol Biol Cell 2006; 17: 394051.
  • 43
    Menges CW,McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA(2) receptor. Oncogene 2007; 27: 293440.